

ANALYSIS C-1

Current Fund Revenues
For the year ended June 30, 2017

	<u>Total</u>	<u>Unrestricted</u>	<u>Restricted</u>
State appropriations-			
General	\$ 15,896,101	\$ 15,896,101	\$ -
Dedicated	86,293	86,293	-
Total state appropriations	<u>15,982,394</u>	<u>15,982,394</u>	<u>-</u>
Government grants and contracts-			
Federal	23,856,397	-	23,856,397
State	1,904,229	-	1,904,229
Total government grants and contracts	<u>25,760,626</u>	<u>-</u>	<u>25,760,626</u>
Private grants and contracts	<u>7,782,280</u>	<u>-</u>	<u>7,782,280</u>
Gifts	<u>2,923,112</u>	<u>-</u>	<u>2,923,112</u>
Sales and services of educational departments-			
Clinical and chemical analysis	368,233	368,233	-
Exercise testing core	26,707	26,707	-
Facility user fees	195,536	-	195,536
Genomics core lab	24,516	24,516	-
Miscellaneous	14,950	14,950	-
Neurobiology and nutrition	45,870	5,610	40,260
Transgenics core lab	12,500	12,500	-
Total sales and services of educational departments	<u>688,312</u>	<u>452,516</u>	<u>235,796</u>
Auxiliary enterprise revenues-	<u>1,601,089</u>	<u>-</u>	<u>1,601,089</u>
Other sources-			
Interest on investments	25,553	-	25,553
Miscellaneous	316,993	582	316,411
Recovery of indirect costs	8,169,908	392,463	7,777,445
Royalties	37,107	-	37,107
Total other sources	<u>8,549,561</u>	<u>393,045</u>	<u>8,156,516</u>
Total revenues	<u>\$ 63,287,374</u>	<u>\$ 16,827,955</u>	<u>\$ 46,459,419</u>